Research programme: TriKE therapeutics - GT Biopharma
Latest Information Update: 26 Apr 2023
At a glance
- Originator University of Minnesota
- Developer GT Biopharma
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 05 Apr 2023 Preclinical trials in Haematological malignancies in USA (Parenteral) prior to April 2023 (GT Biopharma pipeline, April 2023)
- 05 Apr 2023 Preclinical trials in Solid tumours in USA (Parenteral) prior to April 2023 (GT Biopharma pipeline, April 2023)
- 25 Jul 2016 Oxis Biotech enters into an exclusive license agreement with the University of Minnesota to develop and commercialise therapies using Trispecific Killer Engager technology